Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-16 · accession 0001714899-23-000105 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2023-06-20	2023-06-16	DNLI	Watts Ryan J.	Pres, CEO, Dir	M - OptEx	$0.68	+50.0K	2.29M	+2%	+$34.0K
DI	2023-06-20	2023-06-16	DNLI	Watts Ryan J.	Pres, CEO, Dir	S - Sale+OE	$31.40	-50.0K	2.24M	-2%	-$1.57M
D	2023-06-20	2023-06-16	DNLI	Watts Ryan J.	Pres, CEO, Dir	M - OptEx	$0.00	-50.0K	1.12M	-4%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-06-16	M	A	50,000	$0.68	2,289,913	I See footnote	—	—	(F1) The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
2	Common	Common Stock	2023-06-16	S	D	50,000	$31.40	2,239,913	I See footnote	—	—	(F1) The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
3	Derivative	Stock Option (right to buy)	2023-06-16	M	D	50,000	$0.00	1,120,617	D	$0.68 · — to 2025-08-20	50,000 Common Stock	(F4) The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.